Alentis Therapeutics

1.1 Identity and platform

Alentis presents itself as a clinical-stage biotech focused on Claudin-1 (CLDN1), with two related but distinct development franchises: ADCs for CLDN1-positive solid tumors and antibodies for fibrotic disease. Its public site describes the mission as treating cancer and reversing fibrosis, while the investment profile identifies Basel, Switzerland as headquarters and attributes the company to research at the University of Strasbourg and Inserm. The platform is therefore more specific than a generic oncology biotech: the same target biology is used for tumor-selective payload delivery and for anti-inflammatory or anti-fibrotic signaling. External scientific review supports CLDN proteins as emerging therapeutic targets, but also discloses inventor and company relationships that matter when assessing independence. [CO001, CO002, CO003, CO004, CO005]

1.2 Leadership and governance

The disclosed leadership story combines continuity with a material 2025 transition. Mark Pruzanski became CEO after Roberto Iacone's tenure from 2020, with Luca Santarelli identified as board chair; the appointment notice describes Pruzanski's prior experience at Versanis Bio and Intercept Pharmaceuticals. The public site says a board and scientific advisory board support the executive team, but the assigned evidence does not enumerate those bodies or publish a complete governance charter. Key-person dependence is consequently meaningful: platform continuity is supported by specialist leadership, while the public record leaves succession depth, committee responsibilities, and oversight mechanics only partly observable. The founding science also remains closely linked to Thomas Baumert's Strasbourg and Inserm research, making scientific continuity and IP stewardship important diligence questions. [CO003, CO006, CO020]

1.3 Financing and scale

The strongest public scale signal is financing rather than commercial revenue. Novo Holdings reported an oversubscribed $181.4 million Series D in November 2024, led by OrbiMed with Novo Holdings and Jeito Capital as co-leads, and stated that proceeds would fund Phase 1/2 work for ALE.P02 and ALE.P03. Fierce Biotech separately described the round as $181.4 million and noted a prior $105 million Series C, giving a disclosed minimum of $286.4 million across those two rounds; this is not a complete lifetime-raising figure. In October 2026, CSL announced a $355 million initial payment and up to $1.2 billion in commercial milestones for lixudebart, with 55%/45% profit sharing, but contingent milestones are not cash available. No public source in this pool establishes valuation, current cash, burn, runway, revenue, customers, or headcount. [CO010, CO011, CO013, CO014]

1.4 Milestones and underwriting gaps

Alentis has crossed several development milestones: founding research at Strasbourg and Inserm; Series C and Series D financing; FDA IND clearance and Fast Track designation for ALE.P02; initial clinical evidence for lixudebart; the appointment of Mark Pruzanski; and the CSL collaboration. The 2026 partnership materially changes execution capacity for the fibrosis program because CSL is described as funding Phase 2 and Phase 3 development, while Alentis retains the oncology ADC pipeline. However, the positive clinical signals remain early and partly company-reported: the available summaries describe 26 AAV-RPGN patients and 41 advanced-fibrosis patients, and a trade analysis notes that the interim results were not peer-reviewed or fully published. The central underwriting gaps are therefore human efficacy durability, cash and runway after the financing and partnership, valuation terms, and complete governance enumeration. [CO015, CO016, CO017, CO018, CO020]

1.5 Exhibits

2.1 Market boundary and status quo

The relevant market is not “all oncology” or “all fibrosis.” It is the addressable use of CLDN1-directed medicines in selected CLDN1-expressing squamous cancers and in organ-fibrosis or rare immune-mediated diseases where exposed claudin-1 is a proposed therapeutic target. Alentis describes ALE.P02 as an ADC for advanced or metastatic CLDN1-positive squamous cancers, including lung, head and neck, cervical, and esophageal cancers. Lixudebart is being developed for AAV-RPGN, FSGS, PSC, and other fibrotic diseases. Current treatment, surveillance, immunosuppression, supportive care, and physician-directed alternatives remain the status quo; no source in the pool establishes a reimbursed price or share for Alentis. The resulting boundary is indication-specific and biomarker-constrained, not a population-wide pharmaceutical market.[CM001, CM002, CM003]

2.2 Evidence-constrained sizing lenses

Multiple lenses show why a conventional top-down TAM would overstate near-term opportunity. The JCI review reports that MASLD affects 30%–40% of the world’s population, but also describes disease heterogeneity, diagnostic difficulty, and only one approved MASH drug as of its April 2025 publication. That broad fibrosis context is not equivalent to lixudebart’s eligible population. Population statistics provide narrower reference points: SEER projects 42,340 new US liver and intrahepatic bile duct cancer cases in 2026, while the American Cancer Society projects 22,530 new US esophageal cancer cases. Neither figure is a CLDN1-positive prevalence estimate or a forecast of Alentis revenue. A constrained opportunity case therefore needs biomarker prevalence, eligible-line definitions, treatment duration, price, and payer access evidence.[CM004, CM005, CM006, CM007]

2.3 Buyer, payer, and adoption path

The immediate adoption path is specialist and evidence-led. Patients are identified through oncology or nephrology/hepatology workflows; treating specialists and clinical trial networks are the users; payers and health systems ultimately control reimbursement. For lixudebart, CSL’s agreement with Alentis brings global development and commercialization capabilities in nephrology, while CSL and Alentis will co-develop and co-promote the asset. The agreement also covers parallel development in AAV-RPGN, FSGS, and PSC, which broadens the indication portfolio but increases execution and evidence requirements. For ALE.P02, FDA Fast Track applies to advanced or metastatic CLDN1-positive squamous cancers irrespective of organ origin; biomarker testing and demonstration of benefit remain prerequisites to adoption. No public source here supports a customer, payer, or pricing commitment.[CM008, CM009, CM010]

2.4 Drivers, constraints, and valuation relevance

The strongest market driver is unmet need in severe or progressive disease. CSL states that AAV-RPGN can cause rapid kidney-function loss and end-stage renal disease despite potent immunosuppression; the JCI review likewise describes fibrosis as the histologic feature of MASH that correlates with clinical outcomes. The principal adoption constraints are clinical validation, biomarker selection, safety, and the need to establish benefit in separate diseases rather than extrapolating across organs. The partner announcement reports interim results from only 26 AAV-RPGN patients and 41 patients with advanced liver fibrosis, and the independent trade summary notes that the interim results were not peer-reviewed or published in full. The $355 million upfront and up to $1.2 billion in commercial milestones indicate partner willingness to fund development, but milestones are contingent and do not establish market size, cash available, or realized revenue.[CM011, CM012, CM013, CM014]

2.5 Exhibits

3.1 Landscape and strategic position

Alentis competes in two overlapping arenas: precision oncology ADCs and anti-fibrotic antibodies. Its direct position is unusually narrow because the company describes itself as the “CLDN1 company” and is advancing ALE.P02 and ALE.P03 against CLDN1-positive squamous tumors while lixudebart addresses fibrosis. The oncology market already has a validated claudin-targeting precedent: a 2026 Nature Reviews Cancer review states that “a monoclonal antibody targeting the CLDN18.2 isoform has reached clinical approval,” which establishes target-family feasibility but not CLDN1 efficacy. Alentis therefore faces adjacent competition from other CLDN-directed modalities, additional competition from ADCs against different antigens and payloads, and status-quo competition from standard chemotherapy or approved targeted regimens. In fibrosis, CSL is now a development and commercialization partner rather than a direct peer, improving distribution power while also making execution dependent on a large pharmaceutical collaborator.[CP001, CP002, CP003, CP004]

3.2 Capability, product and evidence comparison

The differentiator Alentis claims is not merely the CLDN1 antigen but the proposed disease-state selectivity: its ADC targets a unique CLDN1 epitope exposed on cancer cells, while the company says healthy-tissue CLDN1 is hidden in tight junctions. That mechanism could create a therapeutic-window advantage, but it remains a hypothesis until clinical safety, response and biomarker data are disclosed. ClinicalTrials.gov shows that the ALE.P02 study is designed to assess safety, pharmacokinetics, pharmacodynamics, preliminary anti-tumor activity and a recommended Phase II dose, so the current evidence level is still dose-finding rather than comparative efficacy. ALE.P03 uses a different topoisomerase-I payload from ALE.P02's tubulin inhibitor, creating internal payload optionality but not yet a proven moat. Public sources do not disclose realized pricing, contracting terms, head-to-head response, or validated CLDN1 positivity rates; those cells remain unknown rather than favorable by default.[CP005, CP006, CP007, CP008, CP009]

3.3 Switching costs, channels and moat durability

Switching costs in oncology will be set by clinical outcomes, biomarker testing workflow, tolerability and physician confidence rather than by software-style lock-in. A central laboratory CLDN1 analysis is required in the registered ALE.P02 study, making assay validation, tissue access and screening throughput potential adoption constraints. Alentis has a meaningful distribution advantage in fibrosis because CSL agreed to fund Phase II and Phase III work and to co-develop and co-promote lixudebart, but the deal also allocates 55% of global profits to CSL and 45% to Alentis. That arrangement adds commercial reach while reducing Alentis's control of downstream economics. The moat is more durable if the company demonstrates reproducible CLDN1 selection, differentiated safety and durable responses across tumor types; it is more fragile if other claudin targets, alternative ADC payloads, or standard therapies deliver better efficacy. Independent reporting described only 26 subjects in RENAL and 41 subjects in FEGATO, while noting that the RENAL interim analysis had not been peer reviewed in full. Independent literature also cautions that CLDN1 biology can be context-dependent across cancers, so target validation should not be generalized from one tumor type.[CP010, CP011, CP012, CP013, CP014]

3.4 Competitive verdict and diligence priorities

Alentis has a credible strategic wedge but not a demonstrated competitive moat. The positive signals are a focused target thesis, two distinct oncology payloads, a registered Phase I/II program, and a CSL partnership that can fund and distribute the lead fibrosis asset. The disconfirming evidence is equally material: the clinical study is designed to establish safety and preliminary activity, public data remain limited, and a review of claudin biology reports conflicting roles for CLDN1 in different cancer contexts. Competitor comparisons should therefore be read as evidence of positioning, not proof of superiority. The next underwriting milestones are a reproducible CLDN1 assay funnel, peer-reviewed human response and safety data for ALE.P02, payload-specific differentiation versus other ADCs, and evidence that CSL can translate partnership funding into regulatory and commercial progress.[CP014, CP015, CP016]

3.5 Exhibits

4.1 Revenue model and public traction

Alentis is developing investigational medicines rather than selling an approved product, so public evidence supports a pipeline-financing model rather than recurring commercial revenue. The company describes a clinical pipeline of anti-Claudin-1 ADCs and antibodies, with ALE.P02 and ALE.P03 in oncology and lixudebart in fibrosis; the official pipeline labels the oncology programs as ongoing clinical studies and lists additional fibrosis indications as planned. Synapse's organization snapshot similarly places lixudebart in Phase 2 and ALE.P02/ALE.P03 in Phase 1/2, but its data are an external database view and should not be treated as audited company financials. No retained source supplies revenue, ARR, commercial units, customers, realized pricing, or gross margin. The appropriate financial question is therefore whether partnered economics and financing proceeds can fund clinical execution through value inflection, not whether current operating metrics resemble a software or marketplace company.[CI001, CI002, CI003, CI004]

4.2 Monetization and partnership economics

The October 2026 CSL transaction is the clearest public monetization signal: BioPharm International reports a $355 million initial payment, up to $1.2 billion in commercial milestones, and a 55% CSL/45% Alentis global-profit split for lixudebart. The payment is a collaboration consideration, not recognized revenue or cash available for every corporate purpose; the milestones are contingent and the source does not establish accounting treatment, timing, or remaining obligations. Alentis's official pipeline says CSL will co-develop and co-commercialize lixudebart in rare kidney and liver diseases while Alentis retains its oncology ADC programs. The earlier Series D was $181.4 million and was described as funding Phase I/II development and general corporate purposes. Together these transactions create a plausible capital and partnering route, but they do not establish realized product economics or a forecast of net cash.[CI005, CI006, CI007, CI008]

4.3 Cost structure and capital adequacy

Public evidence indicates a capital-intensive clinical operating model: the 2024 financing was earmarked for Phase I/II trials of ALE.P02 and ALE.P03 plus pipeline development, while the CSL report says CSL will fund specified lixudebart Phase 2, Phase 3, FSGS, and PSC trials. The official pipeline still shows multiple clinical and planned programs, so trial execution, CMC, regulatory, personnel, and overhead costs remain central drivers even where amounts are undisclosed. The Series D article says proceeds also covered general corporate purposes, but neither it nor the CSL coverage discloses current cash, quarterly burn, runway, debt, working-capital needs, or capex. BioPharm International reports interim RENAL data from 26 patients and FEGATO data from 41 patients; those enrollment figures show development activity, not a cost forecast or efficacy proof. Financial underwriting should therefore model program-by-program cash needs and partnership cost-sharing rather than infer runway from headline financing.[CI009, CI010, CI011, CI012]

4.4 Financial verdict and diligence blockers

Alentis has strengthened capital access through a large Series D and a major partnered asset, but the public record remains insufficient for a conventional revenue, margin, or cash-runway underwriting. The CSL upfront is economically meaningful, yet its contingent milestone structure and profit-sharing terms leave timing, net proceeds, and development obligations uncertain. Clinical-stage execution also exposes the company to trial duration, enrollment, regulatory, and manufacturing cost overruns. An independent JCI review further cautions that disease heterogeneity can cause therapies to work differently across patient groups, reinforcing that clinical success cannot be inferred from disease burden or early-stage activity. The financial verdict is therefore capital-supported but disclosure-constrained: partnership validation lowers near-term financing pressure for lixudebart, while the oncology portfolio and corporate platform still require private budgets, burn data, and milestone-by-milestone forecasts before valuation can be assessed with confidence.[CI013, CI014, CI015, CI016]

4.5 Exhibits

5.1 Platform and mechanism

Alentis frames its product thesis around exposed, non-junctional Claudin-1 (CLDN1), using the same target biology across oncology and fibrosis while changing the therapeutic format. The company describes antibodies that target exposed CLDN1 to open the stiff extracellular matrix, block disease signaling, and selectively kill tumor cells. Peer-reviewed translational work with disclosed Alentis ties supplies a more specific mechanism: an antibody against a conformation-dependent epitope of exposed non-junctional CLDN1 reverted inflammation-induced profibrogenic signaling and cell fate and suppressed hepatic stellate-cell myofibroblast differentiation in patient-derived and humanized models. This supports biological plausibility, not clinical efficacy. The platform's main technical promise is target coherence; its main risk is that tumor expression, epitope accessibility, payload exposure, and therapeutic window must all hold in humans.[CE001, CE002, CE003, CE004]

5.2 Pipeline and clinical workflow

The product map has two clinical branches. ALE.P02 is an investigational CLDN1-targeted ADC for advanced or metastatic CLDN1-positive squamous cancers, with a tubulin inhibitor linked to an antibody that recognizes a unique CLDN1 epitope exposed on cancer cells. ALE.P03 is another CLDN1 ADC entering first-in-human development, with the public trial record specifying monotherapy in selected advanced or metastatic CLDN1-positive solid tumors and measuring safety, response, survival, pharmacokinetics, and immunogenicity. Lixudebart, formerly ALE.F02, is the fibrosis branch: an anti-CLDN1 monoclonal antibody being advanced with CSL across AAV-RPGN, FSGS, and PSC. The workflow therefore moves from biomarker-defined patient selection to dose escalation, target and exposure measurements, and disease-specific efficacy readouts; public sources do not disclose the operational assay vendor, cutoff, turnaround, or screen-failure funnel.[CE005, CE006, CE007, CE008, CE009]

5.3 Maturity, deployment, and dependencies

Maturity is heterogeneous rather than a single platform-wide stage. The 2026 ClinicalTrials.gov record is a government registry for ALE.P03 and reports a sponsor of Alentis Therapeutics AG, a last update posted on 2026-07-02, and planned phase I/II outcome collection extending up to four years. The 2026 CSL collaboration adds a material development and commercialization dependency for lixudebart: CSL is described as funding phase 2 and phase 3 work and sharing global profits, while Alentis retains ALE.P02 and ALE.P03. The older Series C release records that the platform was being set up to engineer ADCs and bispecific antibodies, but it does not establish current manufacturing readiness. There is no public evidence here for validated commercial manufacturing, release specifications, batch comparability, uptime, integration, or customer-support operations; those are diligence dependencies, not absent-by-proof facts.[CE010, CE011, CE013]

5.4 Differentiation, controls, and open risks

Differentiation rests on a narrow target thesis, licensed foundational research, and a multi-format pipeline rather than on a disclosed software or manufacturing moat. The Science Translational Medicine paper states that patents covering anti-CLDN1 antibodies and fibrotic disease applications were licensed to Alentis, while also disclosing author and employee interests that should temper independence assessment. The FDA Fast Track announcement is a regulatory designation, not proof of safety or efficacy, and the ClinicalTrials.gov record shows that ALE.P03 is still being evaluated. The product risk stack is therefore clinical translation, biomarker selection, ADC payload and linker execution, and partner governance. Public materials also do not provide a security, privacy, cybersecurity, or incident-control surface; for a regulated biotech this is a documentation gap to close through technical, quality, and vendor diligence rather than a claim that controls do not exist.[CE014, CE015, CE016, CE017]

5.5 Exhibits

6.1 Customer and user segments

Alentis serves a clinical ecosystem rather than a conventional software customer base. The immediate users are investigators and clinical sites treating adults with selected CLDN1-positive advanced or metastatic solid tumors, while the prospective payer and commercial customer is a biopharmaceutical partner capable of funding late-stage development and commercialization. The ALE.P03 registry identifies a multicountry, multicenter footprint and lists 41 recruiting locations across eight country or region groupings. That footprint is evidence of recruitment access and site participation, not evidence of completed deployments, product revenue, or patient outcomes. In fibrosis, CSL is the disclosed strategic customer-like counterparty: the collaboration covers co-development, co-promotion and global profit sharing. No public source in this pool provides a customer count, payer mix, contract value beyond the deal terms, or a denominator for commercial concentration.[CU001, CU002, CU003, CU004]

6.2 Adoption and clinical traction

The observable adoption trajectory is clinical-stage progression, not recurring commercial usage. The ALE.P03 study is listed as recruiting, interventional and Phase 1/Phase 2, with estimated enrollment of 180 participants and a broad set of named recruiting facilities. The lixudebart evidence describes an ongoing Phase 2 RENAL study and a Phase 1b FEGATO study, while the CSL agreement commits funding to additional Phase 2 programs and a planned Phase 3 program. These are meaningful signals that investigators and a global partner have accepted the development proposition, but they do not establish enrollment completion, conversion from screening to dosing, persistence, renewal, or market demand. The small interim RENAL and FEGATO samples reported in the available coverage also limit what can be inferred about future adoption. The chapter therefore treats clinical participation as an adoption proxy and keeps commercial traction unverified.[CU005, CU006, CU007, CU008]

6.3 Named customer proof table

Named proof is strongest where the source identifies a counterparty, study sponsor, trial sites, or a concrete development role. CSL is a named global collaboration counterparty, and the clinical registry names Alentis as sponsor and lists recruiting hospitals. The evidence supports active execution of a clinical program and partner willingness to fund it, but not a marketed therapy or a customer reference with independently measured outcomes. The Fast Track and IND materials are regulatory and company disclosures about investigational assets; they should not be read as approval, sales, or customer satisfaction. The available customer-proof set is therefore partial: it demonstrates named participation and access to clinical channels while leaving treatment completion, safety outcomes, and post-trial adoption open.[CU009, CU010, CU011, CU012]

6.4 Durability, expansion, and concentration

The CSL arrangement creates a potential expansion loop from Alentis discovery and early clinical work into partner-funded Phase 2 and Phase 3 development, co-promotion, and global profit sharing. It also reduces near-term dependence on self-funded development for the disclosed lixudebart indications. However, the same structure creates counterparty concentration: the public record identifies one major strategic partner, and no source here discloses the share of future economics represented by CSL, termination rights, minimum commitments, or the status of any additional commercial partners. For oncology, a recruiting trial is a channel signal but not a retention cohort. NRR, GRR, churn, renewal rates, contract length, repeat purchase, payer coverage, and top-account exposure are not publicly established. Underwriting should therefore give credit for partner validation and financing support while treating durable customer pull and concentration as unresolved.[CU013, CU014, CU015, CU016]

6.5 Exhibits

7.1 Clinical and regulatory execution

The central risk is that Alentis must translate a novel CLDN1 mechanism into reproducible benefit across multiple diseases and modalities. The company describes ALE.P02 as an investigational ADC for CLDN1-positive squamous cancers, while lixudebart is being developed in rare kidney and liver diseases. Publicly described lixudebart evidence is early: the RENAL interim analysis covered 26 patients and the FEGATO study 41 patients, and the report carrying those figures says the results were not peer-reviewed or published in full. The registered ALE.F02 liver-fibrosis study uses dose escalation, placebo, pharmacokinetic endpoints, and adverse-event monitoring, so it is useful for characterization but not proof of efficacy. ALE.P02 also depends on biomarker selection; NCI explains that biomarker tests can fail because tissue is insufficient, no matching therapy exists, or biomarkers differ across tumor cells or change over time. Fast Track and IND milestones therefore reduce process friction but do not remove clinical or diagnostic risk.[CR001, CR002, CR003, CR004, CR005]

7.2 Operating quality, safety, and dependency exposure

Operational risk is concentrated in dose selection, CMC reproducibility, clinical recruitment, and reliance on external development capacity. FDA Project Optimus states that poorly characterized oncology dose and schedule can create more toxicity without additional efficacy, drive dose reductions, cause premature discontinuation, and limit later treatment options. That is directly relevant to an ADC entering early clinical development, although the FDA page does not assess ALE.P02 specifically. The public ClinicalTrials.gov record for ALE.F02 specifies sequential assignment, four staggered cohorts, a safety review committee, and continuous IV dosing, making safety review and operational execution important dependencies. Alentis says its pipeline spans oncology ADCs and antibodies, but the assigned sources do not disclose linker analytics, drug-to-antibody ratio, scale-up reproducibility, site performance, or incident history. Those omissions are gaps, not evidence that no issue exists. Trial participation also carries time, discomfort, and risk, as NIH explains, which can affect recruitment and retention in rare diseases.[CR006, CR007, CR008, CR009, CR010]

7.3 Capital, partner, and thesis-break risks

The CSL collaboration improves external validation and may fund later lixudebart development, but it also creates counterparty, governance, and milestone-dependence risk. Trade coverage describes a $355 million initial payment, up to $1.2 billion in commercial milestones, and a 55% CSL/45% Alentis global profit split; the milestone amount is contingent rather than cash available today. CSL is described as funding phase 2 and phase 3 trials and leading global commercialization, so delays or strategic reprioritization could affect Alentis's path even if the science remains promising. Public company-data pages estimate revenue, employees, and funding, but those figures are explicitly estimates and are not audited cash, burn, runway, or valuation disclosures. A thesis break would be signaled by inadequate biomarker screenability, unacceptable dose-limiting toxicity, failure to reproduce organ-function signals in controlled studies, partner non-performance, or financing terms that expose dilution and runway pressure. The next diligence step is a current cash plan, CMC package, trial-level data, and signed collaboration mechanics.[CR011, CR012, CR013, CR014, CR015, CR016]

7.4 Exhibits

8.1 Recommendation and investment thesis

The evidence supports a track/research-more recommendation with medium confidence and high risk. The positive thesis is that Alentis financed two oncology ADC programs, obtained FDA Fast Track designation for ALE.P02, and secured a strategically significant lixudebart collaboration. The agreement specifies a $355 million initial payment, up to $1.2 billion in contingent commercial milestones, and a 55%/45% global-profit split in CSL's favor. The anti-thesis is that these transaction terms are not an equity valuation, the largest milestone figure is not guaranteed cash, and disclosed clinical evidence remains early. Price discipline therefore matters more than headline capital: no buy case is supportable until round terms, current capitalization, runway, and cohort-level efficacy and safety evidence are available.[CV001, CV003, CV004, CV005, CV007, CV008, CV009, CV015]

8.2 Financing context and entry discipline

Independent financing coverage consistently places the Series D at approximately $181 million in November 2024 and says the proceeds were intended to launch or advance ALE.P02 and ALE.P03 clinical trials. The current partnership changes the financing context because CSL is reported to fund specified Phase 2 and Phase 3 programs, but it does not reveal Alentis's current cash, net burn, equity value, ownership sold, or liquidation preferences. Public evidence also does not show whether the initial payment has been received net of obligations. An investable entry therefore requires the executed financing and collaboration documents, a cash bridge through decisive readouts, and ownership modeling across the preference stack. Funding raised and potential milestones should not be treated as cash available or as a substitute for a priced valuation.[CV001, CV002, CV004, CV005, CV006, CV012, CV016]

8.3 Scenarios and comparable context

A milestone-adjusted clinical scenario framework is more suitable than a revenue multiple because Alentis is a private clinical-stage company without disclosed commercial revenue in the retained evidence. The bull case requires reproducible clinical benefit, acceptable safety, and continued program funding; the base case assumes partnership-supported development while pivotal proof and oncology readouts remain pending; the bear case assumes efficacy, safety, CMC, or financing setbacks. CRISPR Therapeutics had a reported $4.77 billion public market capitalization on October 23, 2026, but that observation is only directional context: public liquidity, a different modality and maturity, and company-specific clinical progress prevent a direct read-through to Alentis. No numeric Alentis valuation range or probability can be defended from the assigned public evidence.[CV006, CV007, CV008, CV009, CV011, CV013, CV014]

8.4 Exit readiness, diligence asks and thesis breaks

The CSL transaction creates a credible strategic-validation signal, but exit readiness remains conditional rather than demonstrated. The retained sources establish active clinical programs and external funding commitments; they do not establish pivotal efficacy, a regulatory filing timetable, a liquid secondary market, or terms for an acquisition or public offering. Diligence should prioritize the Series D cap table and preferences, current cash and monthly burn, collaboration milestones and termination rights, trial-level efficacy and safety, manufacturing readiness, and financing needs through pivotal data. Thesis-break triggers are failure to reproduce clinical benefit, a material safety or CMC setback, loss or narrowing of CSL support, or financing terms that transfer disproportionate value to new capital. Positive movement requires both better evidence and an entry price that preserves target return.[CV003, CV006, CV007, CV008, CV009, CV011, CV012, CV015, CV016]

8.5 Exhibits